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Adoptive immunotherapy using TCR gene modiﬁed T cells may allow separation of beneﬁcial Graft versus tumour responses from
harmful GvHD. Improvements to this include methods to generate high avidity or high aﬃnity TCR, improvements in vector
design and reduction in mispairing. Following adoptive transfer, TCR transduced T cells must be able to survive and persist in
vivo to give most eﬀective antitumour responses. Central memory or naive T cells have both been shown to be more eﬀective than
eﬀectorcellsatexpandingandpersistinginvivo.LymphodepletionmayenhancepersistenceoftransferredTcellpopulations.TCR
gene transfer can be used to redirect CD4 helper T cells, and these could be used in combination with CD8+ tumour speciﬁc T
cells to provide help for the antitumour response. Antigen speciﬁc T regulatory T cells can also be generated by TCR gene transfer
and could be used to suppress unwanted alloresponses.
1.Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT)
is an eﬀective treatment for many haematological malig-
nancies. In addition, unselected donor lymphocyte infusions
(DLIs)canbeutilizedtosuccessfullytreatrelapsedleukaemia
after HSCT [1]. Depending on the degree of HLA mismatch,
donor T cells recognize alloantigens derived from allogeneic
MHC or from polymorphic minor histocompatibility anti-
gens (mHags) expressed by the host. Whilst able to deliver
beneﬁcial Graft versus Tumour eﬀects (GvT), alloreactive T
cells may also direct their response against normal tissues re-
sulting in Graft versus Host Disease (GvHD), and this is
oneoftheleadingcausesoftransplant-relatedmorbidityand
mortality. The incidence of GvHD can be reduced by utiliz-
ing T-cell-depleted transplants-but this also leads to an in-
crease in disease relapse rate [2–4]. How best to deliver eﬀec-
tive GvT responses whilst minimizing harmful GvHD re-
mains a signiﬁcant challenge.
Reﬁning the concept of donor lymphocyte infusions by
isolating donor lymphocytes that have known tumour reac-
tivity may result in more eﬀective GvT. Falkenburg et al. have
utilized donor-derived leukaemia reactive cytotoxic T lym-
phocytes (CTLs) to treat a patient with relapsed accelerated
phase CML after HSCT [5]. The patient, who had previously
been resistant to DLI, went on to achieve a complete remis-
sion as a result of this therapy. A phase I/II study looking
at generating leukaemia reactive CTLs for patients with re-
lapsed leukaemia after HSCT found that whilst this strategy
was feasible, it was complex and time consuming requiring
improvements before becoming a deﬁnitive treatment strat-
egy [6].
As an alternative to isolating tumour reactive lympho-
cytes, the speciﬁcity of T cells can be redirected by retroviral
gene transfer of T-cell receptor (TCR) genes. This allows T
cells to be generated that are speciﬁc for a deﬁned tumour
antigen presented by MHC. TCR gene transfer using retro-
viruses was ﬁrst demonstrated by Clay et al. who transduced
h u m a nTc e l l sw i t haT C Rt h a tw a ss p e c i ﬁ cf o ram e l a n o m a
antigen presented by HLA-A2. These redirected T cells
had demonstrable antitumour reactivity in vitro [7]. TCRs
targeting a variety of tumour associated antigens (TAA)
have now been used for retroviral transduction of T lym-
phocytes and shown to respond to speciﬁc tumour antigens2 Advances in Hematology
in vitro or provide tumour protection in vivo in murine mo-
dels post adoptive transfer [8–12].
The ﬁrst clinical trial using TCR gene modiﬁed T cells
was for treatment of patients with metastatic melanoma. In
this study, autologous peripheral blood lymphocytes were
transduced with alpha and beta chains speciﬁc for a melano-
ma TAA, MART-1, and adoptively transferred to a cohort
of patients with metastatic melanoma. This resulted in an
objective response rate in 2/15 patients (13%) with both res-
ponders obtaining long-term disease remission [13]. A high-
avidity TCR targeting the same MART-1 epitope has been
developed, and this has led to anti tumour responses in 6/20
(30%) of patients treated. In the same trial, a high avidity
TCR targeting the gp100 melanoma antigen resulted in
tumour regression in 3/16 patients (19%) [14]. TCR-trans-
duced autologous T cells targeting the cancer testis antigen,
NYESO1, have been used to treat patients with metastatic
melanoma and advanced synovial cell carcinoma resulting
in response rates of 45% and 67%, respectively [15]. Despite
this, the response rate is still far below that which has been
achieved using antigen-speciﬁc tumour inﬁltrating lympho-
cytes (TILs). Currently the best objective response rate des-
cribed using autologous TIL in patients with metastatic mel-
anoma is 72%, with 16% achieving complete remission [16].
Clinical trials utilizing TCR-transduced cells for treatment of
haematological malignancies are still awaited, but this may
allowthedeliveryofeﬀectiveGvTresponseswithoutharmful
GvHD eﬀects.
2. GeneratingHigh-Afﬁnityand
High-AvidityTCR-TransducedTCellsand
ReducingMispairing
Improving the therapeutic GvT eﬀect may be achieved by an
increase in the functional avidity of the transduced T cell for
its speciﬁc tumour antigen. Increasing T cell avidity has been
correlated with improved elimination of tumour cells in vivo
[17]. Avidity of the TCR is a function of the level of expres-
sion of the TCR on the T-cell surface and the individual
aﬃnity of the TCR for its cognate peptide-MHC (pMHC).
High-avidity CTLs speciﬁc for TAA may be absent from the
peripheral T cell repertoire as a result of deletion during
thymic selection or tolerance induction following encoun-
ter of TAA in the periphery.
One method to generate high-avidity TAA-speciﬁc CTLs
is to immunize human HLA expressing transgenic mice with
human TAA peptides thus eliciting an immune response
against the human peptide. CTLs that express high-avidity
TCRs can then be selected, and the TCR genes isolated and
used to transduce peripheral human lymphocytes [18, 19].
Alternatively the allorestricted technique can be utilized: T
cell tolerance is self MHC restricted, but peptides presented
in the context of an allogeneic MHC molecule will be able
to stimulate high-avidity CTLs. TAA peptides presented by
MHC molecules of a known HLA haplotype can be used
to stimulate lymphocytes in vitro from a HLA-mismatched
donor, and, from this, antigen speciﬁc high avidity T cells
can be isolated [20, 21].
Naturally occurring TCRs are typically of low aﬃnity,
normally within the range of 1–100μmol [22, 23]. TCRs can
be modiﬁed to increase individual TCR aﬃnity by introduc-
ing amino-acid substitutions into the CDR regions of the
alpha and beta chains, in particular into CDR3 regions that
bind to peptide. TCRs can be selected for increased aﬃni-
ty using yeast or bacteriophage display techniques [24–26].
This has led to the generation of high-aﬃnity TCR which
have aﬃnity of up to 1 million times higher than that
of wild-type TCR but still retain the ability to recognize
speciﬁcpeptideMHC.SomeofthehighaﬃnityTCRsdolose
antigen speciﬁcity as the aﬃnity for pMHC increases, par-
ticularly if the TCR is expressed in CD8+ T cells [25].
Zhao et al. transduced CD8+ and CD4+ T cells with a class
I-restricted TCR speciﬁc for NY-ESO. They found CD8+
cells transduced with high-aﬃnity TCR lost their antigen
speciﬁcity at very high ranges of aﬃnity whilst CD4+ T cells
transduced with high-aﬃnity TCR had a marked increase
in reactivity against speciﬁc pMHC and tumour cell lines
with no evidence of cross-reactivity [27]. One other possible
drawback of increasing TCR aﬃnity is that there may be a
threshold of aﬃnity above which TCR function begins to
plateau or even decrease. Higher-aﬃnity TCRs have a longer
dissociationtimefrompMHC,reducingthenumberofTCRs
b o u n db ya n yg i v e np M H Cw h i c hm a yl e a dt oar e d u c t i o n
in T-cell activation, particularly if antigen is present at low
concentration. Thomas et al. have recently demonstrated
that TCR with aﬃnity above the normal range trigger faster
eﬀector responses than wild-type TCR, but this is associated
with a progressive loss of response to low-density antigen as
aﬃnity increased [28].
Higher surface expression of TCR has been shown to
correlate with an increased responsiveness to speciﬁc antigen
[29–31]. Improvements in vector design have led to an
increased transduction eﬃciency of the introduced alpha
and beta chains leading to an increased surface expression
of the TCR. Commonly the TCR genes are inserted into a
retroviral cassette although the use of lentiviral vectors has
increased. The use of an IRES to link the alpha and beta
chains allows transcription of a single mRNA initiating at
the long terminal repeat (LTR) of the virus. The upstream
gene is translated from the 5  cap and the downstream gene
translated from the IRES element. However this can lead to
diﬀerential expression of the two genes with the downstream
gene being expressed at a lower level [32]. More commonly
genes are now being linked by viral derived 2A oligopeptide
linker sequences [33]. 2A sequences can be inserted between
2 genes within the one vector backbone. The upstream gene
is translated fully, but, upon reaching the 2A sequence, an
interaction between the 2A and the ribosome terminates
translation. The ﬁrst protein is released with the 2A sequence
fused to its C terminus and the ribosome “skips” to the
downstream gene and resumes translation. This can lead to
theproductionofmultiplyexpressedgeneswithinonevector
cassette [34]. Direct comparison of retroviral vectors ex-
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sequences demonstrates that the 2A linker sequences result
in higher expression of TCR genes and improved T-cell func-
tion [35]. Codon optimization of the insert by replacing
rarely used codons with those in more frequent use has also
been shown to increase expression level of introduced TCR
which leads to an increase in tumour protection in vivo [31].
When introducing a new alpha and beta chain into a T
cell, ideally they will pair only with one another. However,
the introduced alpha and beta chains may form mixed het-
erodimers whereby the introduced alpha chain pairs with the
endogenous beta chain and the introduced beta chain pairs
withtheendogenousalphachain.Thiscanleadtotheexpres-
sionof2newTCRspeciﬁcitiesbytheTcellwiththepotential
to target normal tissues as they will not have undergone
selection in the thymus. In addition, this will lead to lower
expression of the correctly paired TCR and thus lower the
functional avidity of the T cell. There are now a number of
methods to reduce mispairing. The introduction of a new
disulphide bond into the constant region of the introduced
alpha and beta chain ensures that these chains will more
eﬃcientlybondwitheachotherandnotwiththeendogenous
TCR chains. This has been shown to reduce mispairing and
improve the functional avidity of T cells [36–38]. Replacing
the constant region of human TCRs with the murine con-
stant region also leads to preferential pairing of the modiﬁed
alpha and beta chains leading to increased expression of the
TCR. As well as preventing mispairing, it has been shown
that murine constant region pairs more eﬃciently with
humanCD3resultinginmoreeﬃcientcompetitionforbind-
ing to CD3 [37]. The combination of murinization of con-
stantregionsandanadditionaldisulﬁdebondhasanadditive
eﬀect on reducing mispairing and increasing surface expres-
sion of the introduced TCR although neither completely
eliminates mispairing [36]. Expression of the introduced
TCR may also be increased by suppression of the expression
of the endogenous TCR. This has been achieved by transduc-
ing human PBMC with a vector which encodes a tumour-
speciﬁc TCR and a small interfering (siRNA) which specif-
ically downregulates the endogenous TCR [39].
TCR gene transfer experiments have demonstrated that
TCR cell surface composition following transduction is de-
pendent on properties of both the introduced TCR and
the existing endogenous TCR. This has been described as
TCR strength, with “strong” TCRs being more eﬃciently
expressed on the cell surface compared to “weak” TCRs. T-
cell strength may be controlled by the intrinsic pairing prop-
erties of the alpha and beta chains and also by their ability to
bind to CD3 [40]. The introduced TCR must compete with
theendogenousTCRpriortoexpressionontheT-cellsurface
forbindingtoCD3.TCRandCD3assembleintoaTCR-CD3
complexwithintheendoplasmicreticulumandoncefullyas-
sembled, exported to the cell surface. The amount of CD3
within the T cell thus is rate limiting for expression of the
introduced TCR. TCR and CD3 can be cotransduced in
order to provide an excess of CD3 and thus increase expres-
sion of the introduced TCR. Recent data has suggested
that the increased surface expression of TCR following co-
transduction of CD3 and TCR leads to an increase in tum-
o u rp r o t e c t i o ni nv i v o( A h m a d i ,B l o o d ,i np r e s s ) .
3.ImprovingSurvivalandPersistence
ofTCR-TransducedTCellsFollowing
Adoptive Transfer
The ability of transduced T cells to persist long-term, mount
robust memory responses and migrate to the site of response
following adoptive transfer is key to successful antitumour
responses. Persistence of transferred tumour reactive T cells
h a sb e e ns h o w nt oc o r r e l a t ew i t ha ne ﬀective therapeutic
eﬀectinadoptiveimmunotherapyutilizingTILfortreatment
of metastatic melanoma [41]. From the earliest trials of
adoptive cellular therapy, it has been demonstrated that
“younger” TIL- that is, those subjected to fewer rounds of
stimulation delivered better antitumour responses. In mouse
models, tumour-speciﬁc CD8+ T cells that had undergone a
number of in vitro stimulations and acquired eﬀector func-
tions were less eﬀective at mediating tumour regression after
adoptive transfer [42, 43]. Cells that had a prolonged period
incultureacquiredaTeﬀectorcellphenotypewithdecreased
expression of cell surface markers associated with traﬃcking
to secondary lymphoid organs, for example, CCR7 and
CD62L and also downregulation of costimulatory receptors
such as CD27 and CD28 [44]. Shorter telomeres were also
associated with a reduction in clinical response and reduced
in vivo persistence [45]. It is becoming increasingly apparent
that the transfer of end stage eﬀector CD8 T cells may not
be desirable for adoptive immunotherapy but that transfer
of naive or memory cell subsets may be more eﬀective.
Naive, central memory (CM) and eﬀector memory (EM)
populations each have distinct phenotypic and functional
characteristics. In vitro stimulation of these subsets induces
their proliferation and diﬀerentiation into cytolytic eﬀector
cells. EM T cells preferentially home to peripheral tissues,
have immediate eﬀector function on antigen rechallenge but
show only poor numeric expansion. They have downreg-
ulated CD62L although maintain expression of CCR7. CM
T cells have high expression of CD62L and CCR7 and thus
can home to and recirculate through secondary lymphoid
organs where they can interact eﬃciently with antigen-pre-
sentingcells.Theyhaveenhancedproliferativecapacityupon
antigen reencounter [43, 46]. A comparison of transfer of
tumour-speciﬁc CM T cells and EM T cells in a murine
model of melanoma showed that CM T cells had more eﬃc-
ient in vivo recall responses compared with EM T cells
which were associated with superior antitumour ability
[43].
Berger et al. looked at the persistence of EM T cells
versus CM T cells following adoptive transfer of CD8+
CMV-speciﬁceﬀectorcellsintounconditionedprimates.The
eﬀector T cells that were derived from EM T cells only
persisted in the blood for a short period and were unable
to persist within lymph node or bone marrow or peripheral
tissues. They were also unable to diﬀerentiate back into an
EM T-cell phenotype. In contrast the eﬀector T cells derived
from CM T-cells were able to persist in blood and could
migratetobonemarrowandlymphnodesandhadtheability
to diﬀerentiate to both CM and EM T cell phenotype. Ef-
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plastic than EM T cells, retaining the ability to revert to both
a CD62L− and CD62+ memory cell phenotype [47].
However, this study did not address the role of naive
T cells for use in adoptive immunotherapy. Hinrichs et al.
utilizing a murine adoptive transfer model have suggested
that naive T cells may be superior to T CM cells. T cells were
isolated from pmel-1 TCR-transgenic mice which express
TCR speciﬁc for self-antigen, gp100 that is also expressed
by murine melanoma cells. Sublethally irradiated mice
with established B16 melanoma tumours received adoptive
transfer of CD8+ naive T cells (CD62L+ CD44low) or CM
T cells (CD62L+CD44high). All mice also received speciﬁc
peptide vaccination and IL-2. Both naive and CM T cells
were able to mediate tumour regression following adoptive
transfer, but eﬀector cells derived from naive T cells had
superior antitumour activity. Adoptively transferred naive
T cells also showed greater expansion within spleen and
drainingLNandalsoproducedhigheramountsofIFN-γ and
IL-2 following ex vivo restimulation [48].
An o v e lw a yt ot r yt op r e v e n tTc e l l sa c q u i r i n gaT
eﬀector phenotype prior to adoptive transfer is to target the
Wnt/Beta Catenin pathway which is thought to be important
in the generation and maintenance of T-cell memory [49].
The Wnt/beta catenin pathway can be activated artiﬁcially
in vitro and in vivo utilizing inhibitors of glycogen synthase
kinase 3β(Gsk-3β). Gsk-3β inhibitors lead to an accumu-
lation of beta catenin which mimics Wnt signaling [50].
Utilizing pmel-1 transgenic T cells, Gattonini et al. primed
naive T cells in the presence of Gsk-3β inhibitors. This
inhibitedcellsfromacquiringaTeﬀectorphenotypeandalso
generated a CD44 low CD62L high T-cell population which
had properties of stem cells, that is, robust self-renewal and
the capacity to generate CM, EM, and eﬀector T cells. They
also had a characteristic phenotype, with high expression
of Sca1, CD122, and Bcl2, previously described by Zhang
et al. as CD8 memory stem cells [51]. Following adoptive
transfer in a tumour model they had superior proliferative
potential and superior antitumour function when compared
to CM T cells or EM T cells [50]. Targeting of Wnt/beta
catenin signaling pathways to generate CD8 memory stem
cells in combination with TCR transduced T cells represents
an attractive strategy for adoptive immunotherapy.
Lymphodepletionasaresultofconditioningtherapypre-
adoptive transfer has been shown to increase persistence of
transferred T cells. Trials in melanoma patients conditioned
with chemotherapy or chemotherapy plus total body irra-
diation demonstrated that inducing lymphopaenia impro-
ved the persistence of the transferred T-cell population [16,
41, 52]. Increasing the level of lymphodepletion in mouse
modelsalsodemonstratedanincreaseinpersistenceofTcells
and improvement in antitumour eﬀect [53]. Lymphodeple-
tionresultsinaspontaneoushomeostaticproliferationofthe
remaining peripheral T cells which can lead to reconstitution
of the peripheral lymphocyte pool [54, 55]. In addition
T cells that are adoptively transferred into lymphopaenic
hosts undergo the same homeostatic proliferation [56]. This
process is dependent on homeostatic cytokines, IL-7 and IL-
15, and also interaction between TCR and self-peptide/MHC
and is similar to normal homeostatic mechanisms that
maintain the peripheral T-cell repertoire [22, 57–60]. The
degree of expansion of T cells following adoptive transfer is
likelytobecontrolledbyaccesstoIL-7andIL-15andalsothe
availability of self-peptide/MHC ligands. T cells which have
ah i g h e ra ﬃnity for self-peptide/MHC may have a selective
advantage in the lymphopaenic environment and undergo
more rapid and eﬃcient expansion [61–63]. This may ben-
eﬁt TCR-transduced T cells speciﬁc for tumour-associated
antigens which are self-antigens, leading to increased prolif-
eration and persistence following adoptive transfer. It may
also be possible to augment this proliferation by increased
exposure to speciﬁc antigen which could be achieved by
peptide vaccination at the time of adoptive transfer which
may also give transferred cells an advantage over non-
antigen-speciﬁc residual host T cells. [64]. It has been shown
that CD4+ CD25+ FoxP3+ T regulatory cells also undergo
homeostatic proliferation and thus may act to control cell
expansion in the lymphopaenic environment [51, 65].
4. The Role of TCR-Transduced
CD4+T Cells inthe Treatmentof
HaematologicalMalignancies
Most adoptive immunotherapy protocols have focused on
thetransferofCD8+tumour-speciﬁcTcells.However,inthe
absence of CD4 help, CD8+ T cells have impaired function,
persistence, and cannot mount eﬀective memory responses
[66–68]. The generation of both TCR-transduced CD8+ and
CD4+ T helper cells may have a beneﬁcial eﬀect on sustained
tumour control (Figure 1).
Quezada et al. explored the role of classical class II-
restricted CD4+ T cells in a murine model of advanced
melanoma. Adoptive transfer of small numbers of naive class
II-restricted tumour speciﬁc CD4+ T cells into irradiated
recipients led to in vivo diﬀerentiation and expansion of
CD4+ T cells and tumour regression. These CD4+ T cells
acquired cytotoxic activity and directly rejected the tumour
in a class II-dependent manner. The eﬃcacy of CD4+ T cells
wasincreasedbyconcurrentblockadeofCTLA-4resultingin
greater expansion of CD4+ T cells and decreased numbers of
Tr e g u l a t o r yc e l l s[ 69].
The use of CD4 + T cells for adoptive immunotherapy is
limited due to a lack of well-characterized tumour antigens
presented by class II MHC. In addition the majority of
tumour cells are class II negative and therefore cannot di-
rectly present antigen to CD4+ T cells. To overcome these
limitations, CD4+ T cells expressing class I restricted TCR
have been generated by gene transfer. It has been demon-
strated that CD4 T cells transduced with class I-restricted
TCR can provide antigen-speciﬁc helper functions. Some
class I-restricted TCRs are independent of the CD8 corecep-
tor and function in CD4+ T cells in the absence of additional
CD8 [19]. However the majority of class I-restricted TCRs
are CD8 dependent and thus require cotransduction of
CD8 to be fully functional in CD4+ T cells. CD8 stabilizes
the interaction between the TCR and peptide-MHC and
increases the duration of this interaction. Kessels et al.
transduced CD4+ T cells with the class I-restricted OT1Advances in Hematology 5
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Figure 1: Populations of antigen speciﬁc T cells that can be generated by TCR gene transfer for use in adoptive immunotherapy. Retroviral
gene transfer can be used to generate diﬀerent populations of T cells for use in adoptive immunotherapy in the setting of haematological
malignancy. Both CD8 and CD4 T cells can be transduced with class I-restricted TCR of the same speciﬁcity, targeting the same tumour
antigen.AlternativelyCD4TcellscanbetransducedwithclassII-restrictedTCR-speciﬁctumourantigenpresentedbyclassIIMHC.Antigen
speciﬁc T regulatory cells can be generated by TCR transduction of CD 4 +C D 2 5 +Tr e g u l a t o r yc e l l so rC D 4 +Tc e l l sc a nb ec o t r a n s d u c e d
with TCR and FOXP3 resulting in production of antigen-speciﬁc converted CD4+ T regulatory cells. Antigen-speciﬁc T regulatory cells
could be adoptively transferred in the context of HSCT or DLI to reduce harmful GvHD responses of T eﬀector cells.
TCR [70]. OT1 TCR CD4+ T cells required cotransduction
of the alpha and beta chains of CD8 in order to respond to
speciﬁc antigen, and the transduction of just the alpha chain
of CD8 was not suﬃcient to provide full CD8 coreceptor
function. Morris et al. transduced CD4+ T cells with a
class I-restricted TCR which is speciﬁc for NP peptide and
is partially CD8 dependent [9]. CD4+ TCR-transduced
T+ cells were able to produce IL-2 and proliferate in vitro
in response to class II-negative tumour cells expressing
speciﬁc peptide, but these cells were not able to generate
an IFN-γ response. In vivo, CD4+ T cells could provide
help for CTL-mediated tumour eradication, and these cells
persisted in vivo for up to 90 days after tumour regression
and were able to reexpand following tumour challenge. The
generation of class I-restricted TCRs is a promising strategy
with the advantage that tumour-speciﬁc CD4+ and CD8+ T
cells targeting the same epitope can be generated.
CD4+ CD25+ FOXP 3+ T regulatory cells (CD4+ T
regs) play a crucial role in the control of GvHD. This has
been demonstrated via the depletion of CD4+ T regs from
donor cells in murine MHC-mismatched transplant models.
Thesetransplantsweredoneusingavarietyofdiﬀerentstrain
combinations, and the depletion of CD4+ T regs resulted
in an increase in GVHD and an increase in mortality [71].
Adoptive transfer of additional CD4+ T regs with T eﬀector
cells is one possible strategy of reducing GvHD burden
after allogeneic transplant. The infusion of freshly isolated
polyclonal CD4+ T regs in a 1:1 ratio with T eﬀector cells
hasbeenshowntoleadtoadelayindevelopmentofGvHDin
a MHC-mismatched murine transplant [72, 73]. Polyclonal
CD4+ T regs can be expanded dramatically ex vivo using
high-dose IL-2 and anti-CD3/CD28 beads or can also be
expanded ex vivo utilizing irradiated allogeneic splenocytes
p r i o rt oa d o p t i v et r a n s f e r .T r e n a d oe ta l .c u l t u r e dC D 4 +
T regs in the presence of allogeneic irradiated splenocytes
which led to a 1000-fold expansion. These alloreactive CD4+
T regs were infused to lethally irradiated mice in a 1:1
ratio with T eﬀector cells in a murine MHC-mismatched
transplant model. This led to complete protection from
GvHD. CD4+ T regs that were expanded using third-party
splenocytes were of much lower eﬃcacy than alloreactive
CD4+ T regs. They also demonstrated that the reduction in
GvHD did not lead to reduction in GvT responses mediated
by CD8+ eﬀector T cells following the injection of A20
leukaemiacelllinestorecipientmiceonthedayoftransplant
[74]. Other groups have also demonstrated the adoptive
transfer of murine CD4+ T regs in addition to HSCT can
reduce GVHD whilst maintaining GVT eﬀects [75, 76].
The use of antigen-speciﬁc CD4+ T regs is more eﬀective
at reducing GvHD than a polyclonal population [77]. CD4+
T regs require to meet speciﬁc antigen in order to be
activatedalthoughonceactivatedcanmediatesuppressionof6 Advances in Hematology
Te ﬀector cells regardless of speciﬁcity. However, if CD4+ T
regs are antigen speciﬁc, this has the advantage that they can
betargetedtothesameantigenastheTeﬀectorcell,targeting
the suppressive response directly to the site of the harmful
eﬀector response. It has been shown that the recruitment
of T regulatory cells to the site of GvHD is critical for the
suppression of alloreactive T cells [78].
Gene transfer of antigen-speciﬁc CD4+ T cells with
FOXP3 is one possible mechanism of generating large num-
bers of antigen-speciﬁc CD4+ T regs. The ectopic expres-
sion of FOXP3 had been shown to convert CD4+ T cells to
regulatory T cells that are phenotypically and functionally
the same as CD4+ T regs. Albert et al. produced CD4+ T
regs by transducing CD4+ CD25- TCR-transgenic cells with
FOXP3 and found that FOXP3-transduced T regs were as ef-
fective as wild-type CD4+ T regs at suppressing GvHD [77].
Antigen-speciﬁc CD4+ T regs may also be generated by
the transduction of a speciﬁc TCR into CD4+ T regs or
also by the cotransduction of both TCR and FOXP3 into
conventional CD4+ T cells. In a mouse model of inﬂam-
matory arthritis, both TCR-transduced T regulatory cells
and FOXP3 and TCR-co-transduced CD4+ T cells were able
to mediate suppressive eﬀects following adoptive transfer
leading to reduction in progression of inﬂammatory arthritis
[79]. There is some concern that CD4+ T regs may convert
following adoptive transfer to TH17 cells thus abrogating
their suppressive function [80]. However FOXP3 and TCR-
co-transduced CD4+ T cells should be a more stable popu-
lation due to the persistent and stable expression of FOXP3
from a strong retroviral promoter.
5.TumourAntigenSelection
In order to develop eﬀective adoptive immunotherapy pro-
tocols, it is important that the correct TAA or epitope is
targeted. The use of high throughput screening of cancer
genomes can identify large numbers of novel TAA, and it is
important that research is focused, leading to more eﬀective
translation of TCR gene therapy and vaccine strategies into
clinical practice. An ideal tumour antigen would be one that
is widely expressed in diﬀerent tumour types and not unique
to individual patients. Targeting tumour antigens that are
essential to the oncogenic process or cancer cell survival may
induce sustained tumour regression. Speciﬁcally targeting a
single epitope, however, may lead to the selection of tumour
variants that lack the target antigen as a result of antigen loss
or aberrant presentation via MHC loss [81–83]. Selecting
a target that does not lead to autoimmune damage will
also be of paramount importance. This has been recently
demonstrated in a study where lymphocytes transduced with
a high-avidity TCR speciﬁc for carcinoembryonic antigen
(CEA) were administered to 3 patients with metastatic
colorectal cancer. All patients in the study developed severe
inﬂammatory colitis as a result of the TCR gene-modiﬁed
T cells recognizing CEA expressed within normal colonic
epithelium [84].
A National Cancer Institute Pilot project has been devel-
oped to try to prioritize antigens for further research and
development [85]. This utilized a methodology termed Ana-
lytic Hierarchy Process (AHP), which breaks down complex
problems into a hierarchy of subproblems allowing com-
parison on a pairwise basis. 75 cancer antigens were ranked
and scored based on criteria that had been deﬁned and given
diﬀerentialweightingsbyapanelofexperts.Thecriteriaused
for ranking (and in order of weighting) were demonstrable
therapeutic function of antigen, known immunogenicity,
oncogenic function, whether antigen is expressed widely or
uniquely by tumour cells, expression level of antigen within
tumours, expression by tumour stem cells, the number of
patientswithantigenpositivecells,thenumberofepitopesof
the tumour antigen and whether it is able to bind to multiple
MHC molecule, and ﬁnally the cellular location of the
antigen. The three top ranked antigens were WT1, MUC1,
and LMP2. The antigens that have already been extensively
researched score higher as there is more supportive evidence
of therapeutic function and immunogenicity. For some of
thesubcriteria,thereexistsonlylimitedinformation,butthis
process is dynamic, allowing reanalysis as further evidence
accrues.
6. Safety Considerations of
T CR - T rans d uc edTC ell s
In addition to reducing the eﬃcacy of TCR transduced T
cells, mispairing is also a concern with regards to safety
of TCR-transferred T cells for clinical use. Bendle et al.
have demonstrated that TCR-transduced T cells can induce
GVHD following adoptive transfer. This is not a result of
the on-target toxicity of the introduced TCR but is a result
of the formation of new heterodimers that have oﬀ-target
toxicity directed against normal tissues [86]. This stresses the
importance of utilizing mechanisms to prevent mispairing of
the introduced alpha and beta chains.
Lymphocytescanbetransducedwithsuicidegeneswhich
enables selective elimination of transduced cells should
GvHD develop following adoptive transfer. The most exten-
sively studied to date is herpes simplex thymidine kinase
(HSV-TK). HSV-TK phosphorylates ganciclovir to a toxic
metabolite which interrupts DNA elongation resulting in
the selective death of cells transduced with HSV-TK follow-
ing the infusion of ganciclovir. When administered to
patients with relapsed haematological malignancy after allo-
geneic HLA-matched HSCT, rates of GvT using HSV-TK-
transduced lymphocytes were comparable to that of DLI
using unmanipulated lymphocytes. The administration of
ganciclovir for treatment of GVHD or for CMV reactiva-
tion selectively eliminated HSV-TK-transduced cells and
improved GvHD [87]. HSV-TK-transduced lymphocytes
have also been investigated as a coinfusion at the time of T-
depleted HLA identical HSCT and also as incremental add
back infusion following haploidentical transplant [88, 89].
Although a promising strategy for control of GVHD after
DLI, the eﬃcacy may be limited due to the immunogenicity
of HSV-TK leading to a decrease in persistence of transduced
cells [90]. In addition the administration of ganciclovir for
treatment of CMV reactivation results in the prematureAdvances in Hematology 7
destruction of HSV-TK-transduced cells leading to loss of
eﬃcacy.
Another suicide gene strategy in development is based
on human apoptosis proteins. A fusion protein consisting
of a late stage apoptosis molecule, caspase 9 fused to a
FK506-binding protein (FK506BP) analogue has been trans-
duced into lymphocytes. Apoptosis of the transduced cells is
induced following the administration of a chemical inducer
of dimerization (CID) which results in aggregation and acti-
vation of caspase 9. The CID which has been used is a non-
toxic FK506 analog which has been modiﬁed so that it has
much higher aﬃnity for the modiﬁed FK506BP than the
endogenous FK506BP. A single dose of CID resulted in death
of >99% of transduced cells both in vitro and in vivo. These
molecules are human derived and therefore should in theory
be less immunogenic than HSV-TK [91].
An additional safety concern of gene therapy is inser-
tional mutagenesis secondary to gene insertion into the host
chromosome leading to disruption or activation of cellular
genes. Out of the 19 X-linked severe combined immuno-
deﬁciency patients treated with retrovirally transduced hae-
matopoietic stem cells there have been 5 cases of T-cell
leukaemia reported [92–94]. In 4 of the 5 cases, the leukae-
mia arose secondary to retroviral integration in the region
of a T-cell oncogene, LMO2, resulting in its deregulated
expression. In these clinical trials, the vector expressed the
IL-2 receptor gamma (IL-2R-γ) chain, and there is some
controversy over whether this gene itself had a role as a coop-
erating oncogene. Insertions near both the LM02 and IL-
2R-γ chain gene have been described in murine T-cell
leukaemia [95]. In addition, adoptive transfer of HSC trans-
duced with lentiviral vectors expressing very high levels of
the IL-2R-γ chain led to a high incidence of lymphoma in
a murine model system [96]. Pike-Overzet et al., however,
have shown that the overexpression of IL-2R-γ chain did not
have any eﬀect on haematopoietic cell development whilst
overexpression of LMO2led to a block in T-celldevelopment
leadingtoapreleukaemicphenotype[97].Modlichetal.also
found that vector-mediated expression of IL-2R-γ chain was
not suﬃcient to lead to induction of leukaemia following
HSCT in mouse models using both lentiviral and retroviral
vectors [98].
All cases of leukaemia arising secondary to insertional
m u t a g e n e s i sh a v ei n v o l v e dt h eu s eo fr e t r o v i r a lv e c t o r s
which have LTRs with strong enhancer/promoters elements.
Strong LTRs may cause the transcription of cellular genes
in addition to the transgene which can lead to unregulated
gene expression. By using self inactivating vectors (SIN), it
maybepossible toreducetheriskofinsertionalmutagenesis.
SIN vectors contain a deletion within the U3 region of the
3 LTR which leads to inactivation of the 5 LTR following
reverse transcription, thus, inactivating both LTRs [99, 100].
Any expression of the transgene is then driven by an internal
promoter. The use of SIN in preclinical models suggests that
they have a lower oncogenic potential [101–103].
Both lentiviral and gamma retroviral vectors integrate
in a semirandom fashion with a bias towards insertion
into transcriptional units. Gamma retroviral vectors tend to
integrate close to transcription start sites or DNA regulatory
areas such as CpG islands. Insertions of viral LTR at these
points willhave a higher probability of causing aberrant gene
expression [104, 105]. In contrast, lentiviral vectors tend to
integrate within active transcription units and as a result
may have a safer insertion proﬁle [106, 107]. Cattoglio et al.
analyzed gammaretroviral and lentiviral vector insertion
“hot spots” in human cord blood and bone marrow derived
CD34+ HSC which had been transduced in vitro. Gamma
retroviral vector integration (but not lentiviral) occurred at
high frequency (i.e., >20%) in “hot spot” areas enriched
in protooncogenes and genes involved in control of cell
proliferation [108]. Using a tumour prone mouse model,
Montini et al. have compared the oncogenic potential of
lentiviral and gamma retroviral vectors, both of which had
equivalent strength LTRs and found that lentiviral vectors
required a 10-fold higher integration load than retroviral
vectors to induce oncogenesis [101]. Only lentiviral vectors
that had an active LTR led to insertional transformation
of HSCs whereas SIN lentiviral vectors did not lead to
transformation above background levels.
The risk of insertional mutagenesis may also be aﬀected
by the cell type being transduced, and there is a lower risk of
transformation by transducing terminally diﬀerentiated cells
asopposedtoHSC.Astudylookingatlong-termfollowupof
patients receiving T cells transduced with thymidine kinase
genes in the context of HSCT demonstrated that up to
20% of gene insertions resulted in altered gene expression
of neighbouring genes, but there had been no incidence of
clonal selection in these cells [109]. To date, there have been
no cases of leukaemia or malignancy arising as a result of
adoptive transfer of gene-modiﬁed T lymphocytes.
7. Conclusion
TCR gene transfer to produce antigen-speciﬁc T cells rep-
resents a targeted approach to treatment of haematolog-
ical malignancies which may generate more speciﬁc GvT
responseswhilstreducingharmfulGvHDresponses.Inaddi-
tion to using TCR-transduced T cells to enhance GvT, we
can also generate antigen-speciﬁc T regs to directly suppress
harmful GVHD responses. Experience from clinical trials of
melanomaantigen-speciﬁcTCR-transducedTcellshashigh-
lighted areas where this technique can be further reﬁned
and improved. Improvements in vector design, generation
of high-avidity TCR, and reduction of TCR mispairing has
all led to improvements in preclinical models. The impor-
tance of phenotype and subtype of the transferred popula-
tion and the host environment into which they are trans-
ferred is becoming increasingly evident. Clinical trials utiliz-
ing WT1 TCR-transduced lymphocytes for treatment of hae-
matological malignancies are due to commence in the near
future hopefully leading to progress translating this tech-
nique into wider clinical use.
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